Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Carl Zeiss Meditec AG : Good timing to anticipate a continuation of the trend

04/08/2021 | 03:01am EDT
long trade
Live
Entry price : 135.2€ | Target : 145€ | Stop-loss : 127€ | Potential : 7.25%
Shares in Carl Zeiss Meditec AG show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Investors have an opportunity to buy the stock and target the € 145.
Carl Zeiss Meditec AG : Carl Zeiss Meditec AG : Good timing to anticipate a continuation of the trend
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 106.7 EUR

Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at EUR 138.3.
  • The stock is close to a major daily resistance at EUR 138.7, which should be gotten rid of so as to gain new appreciation potential.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 63.89 times its estimated earnings per share for the ongoing year.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart
Subsector Other Advanced Medical Equipment & Technology
1st jan.Capitalization (M$)Investor Rating
CARL ZEISS MEDITEC AG27.55%14 800
THERMO FISHER SCIENTIFIC IN..2.19%188 208
DANAHER CORPORATION4.60%165 688
INTUITIVE SURGICAL, INC.-4.75%92 247
SHENZHEN MINDRAY BIO-MEDICA..-7.74%72 973
SIEMENS HEALTHINEERS AG11.91%62 855
ILLUMINA, INC.7.84%58 213
BOSTON SCIENTIFIC CORPORATI..9.43%55 855
KONINKLIJKE PHILIPS N.V.15.21%54 390
EDWARDS LIFESCIENCES CORPOR..-5.74%53 489
AGILENT TECHNOLOGIES, INC.10.79%40 193
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 1 544 M 1 837 M 1 837 M
Net income 2021 194 M 231 M 231 M
Net cash 2021 590 M 702 M 702 M
P/E ratio 2021 64,0x
Yield 2021 0,53%
Capitalization 12 423 M 14 800 M 14 781 M
EV / Sales 2021 7,67x
EV / Sales 2022 6,95x
Nbr of Employees 3 290
Free-Float 40,9%
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 122,17 €
Last Close Price 138,90 €
Spread / Highest target 8,71%
Spread / Average Target -12,0%
Spread / Lowest Target -56,8%
EPS Revisions
Managers and Directors
NameTitle
Ludwin Monz President & Chief Executive Officer
Justus Felix Wehmer Chief Financial Officer
Michael Kaschke Chairman-Supervisory Board
Markus Guthoff Member-Supervisory Board
Christian Müller Member-Supervisory Board